Story thread · 2 reports / 2 sources
Revolution Medicines preps for launching pancreatic cancer drug, ups 2026 expenses
endpts.com · 5d
Revolution Medicines executives say they're ready to launch what is arguably the biopharma industry's most highly anticipated experimental therapy. The drug, daraxonrasib, is awaiting an approval decision from the US and Europe for metastatic pancreatic ...
First report: Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story? — finance.yahoo.com, 7d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.